Controlled document PF-010A
PLEXUS BRACHIALIS Phase 2 Master Formula
TemplateDocumented
Record identification
- Document ID
- PF-010A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-010A
PRODUCT FORMULA CARD
SIRIAM PLEXUS BRACHIALIS DUO – PHASE 2 (NERVE INTEGRATION)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-PB-002 |
| MF-010 |
| PF-010A |
| PLEXUS BRACHIALIS DUO – Phase 2 |
| C5–C8 / T1 |
| Nerve Integration |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
ValueSIR-PB-002
ValueMF-010
ValuePF-010A
ValuePLEXUS BRACHIALIS DUO – Phase 2
ValueC5–C8 / T1
ValueNerve Integration
ValueTopical Magistral Cream
Value100 g
Value2.0
Value🔒 LOCKED
Value☐
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
| Description |
|---|
| Neurogenic stabilisation and peripheral nerve integration |
| C5–C8 / T1 |
| Fascial glide, autonomic integration and skin recovery |
| Phase 2 – Nerve Integration |
| Topical Magistral Cream |
DescriptionNeurogenic stabilisation and peripheral nerve integration
DescriptionC5–C8 / T1
DescriptionFascial glide, autonomic integration and skin recovery
DescriptionPhase 2 – Nerve Integration
DescriptionTopical Magistral Cream
2. MASTER FORMULA
The formulation follows the Phase 2 magistral fiche with the standardised SQMS ingredient naming.
| Code |
|---|
| Official Ingredient |
| Supplier |
| Master Qty |
| Unit |
| Phase |
| PC-001 |
| Lanette Cream FNA |
| Fagron |
| 67.00 |
| g |
| B |
| PC-002 |
| Aqua Purificata |
| Fagron |
| 16.00 |
| g |
| W |
| SC-001 |
| Magnesium Chloride |
| Fagron |
| 2.00 |
| g |
| W |
| SC-002 |
| MSM |
| — |
| 1.20 |
| g |
| W |
| AC-003 |
| Palmitoylethanolamide (PEA) |
| Vitals |
| 1.00 |
| g |
| D |
| BE-001 |
| Boswellia serrata |
| WeightWorld |
| 1.00 |
| g |
| L |
| BE-010 |
| Hypericum perforatum D6 |
| — |
| 0.30 |
| mL |
| C |
| BE-004 |
| Bacopa monnieri |
| Mattisson |
| 0.50 |
| mL |
| C |
| BE-005 |
| Nymphaea caerulea (Blue Lotus) |
| — |
| 0.15 |
| g |
| C |
| AC-006 |
| α-Bisabolol |
| — |
| 0.25 |
| g |
| L |
| BE-002 |
| Copaiba Oil |
| Aroma-Zone |
| 0.40 |
| mL |
| C |
| AC-002 |
| Betaine (TMG) |
| — |
| 0.80 |
| g |
| W |
| SC-003 |
| D-Panthenol |
| Natural Heroes |
| 1.00 |
| g |
| W |
| SC-004 |
| Vitamin E Full Spectrum |
| Natural Heroes |
| 0.70 |
| g |
| L |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| — |
| 3.00 |
| g |
| C |
| PR-001 |
| Cosgard 221 |
| Aromantic |
| 0.70 |
| g |
| C |
CodeOfficial Ingredient
CodeSupplier
CodeMaster Qty
CodeUnit
CodePhase
CodePC-001
CodeLanette Cream FNA
CodeFagron
Code67.00
Codeg
CodeB
CodePC-002
CodeAqua Purificata
CodeFagron
Code16.00
Codeg
CodeW
CodeSC-001
CodeMagnesium Chloride
CodeFagron
Code2.00
Codeg
CodeW
CodeSC-002
CodeMSM
Code—
Code1.20
Codeg
CodeW
CodeAC-003
CodePalmitoylethanolamide (PEA)
CodeVitals
Code1.00
Codeg
CodeD
CodeBE-001
CodeBoswellia serrata
CodeWeightWorld
Code1.00
Codeg
CodeL
CodeBE-010
CodeHypericum perforatum D6
Code—
Code0.30
CodemL
CodeC
CodeBE-004
CodeBacopa monnieri
CodeMattisson
Code0.50
CodemL
CodeC
CodeBE-005
CodeNymphaea caerulea (Blue Lotus)
Code—
Code0.15
Codeg
CodeC
CodeAC-006
Codeα-Bisabolol
Code—
Code0.25
Codeg
CodeL
CodeBE-002
CodeCopaiba Oil
CodeAroma-Zone
Code0.40
CodemL
CodeC
CodeAC-002
CodeBetaine (TMG)
Code—
Code0.80
Codeg
CodeW
CodeSC-003
CodeD-Panthenol
CodeNatural Heroes
Code1.00
Codeg
CodeW
CodeSC-004
CodeVitamin E Full Spectrum
CodeNatural Heroes
Code0.70
Codeg
CodeL
CodeSC-005
CodeSilicea Gel (+1 drop Silicea D8)
Code—
Code3.00
Codeg
CodeC
CodePR-001
CodeCosgard 221
CodeAromantic
Code0.70
Codeg
CodeC
3. MANUFACTURING WORKFLOW
Identical validated Lanette protocol (SQMS SOP-001).
4. QUALITY CONTROL
Standard SQMS Quality Control checklist.
5. BATCH RELEASE
Standard SQMS Batch Release form.
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Secondary Zone
Additional Zone
Peripheral Pathways
Frequency
Weeks 1–2
Week 3
Week 4
Relapse
| Value |
|---|
| C5–C8 / T1 |
| Supraclavicular |
| Infraclavicular |
| Axillary region |
| Radial, Median and Ulnar nerve trajectories |
| 1–2× daily |
| PLEXUS-1 |
| Morning PLEXUS-2 / Evening PLEXUS-1 |
| PLEXUS-2 |
| 3 days PLEXUS-1 |
ValueC5–C8 / T1
ValueSupraclavicular
ValueInfraclavicular
ValueAxillary region
ValueRadial, Median and Ulnar nerve trajectories
Value1–2× daily
ValuePLEXUS-1
ValueMorning PLEXUS-2 / Evening PLEXUS-1
ValuePLEXUS-2
Value3 days PLEXUS-1
Related documents
Platform modules